Our previous studies found that tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF) protected liver injury by decreasing NF-κB/NLRP3 inflammasome signaling pathways, thereby attenuating liver fibrosis [30]. This evidence concerns the gene NLRP3 and Hepatic fibrosis.